Vasiliki Bravou

Prof. Dr. Vasiliki Bravou

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2018 in Cancer Genomics & Proteomics
Verified
Journal Article
Open access
PDF file
DTDimitrios Tsoumas
Dimitrios Tsoumas
SNSofia Nikou
Sofia Nikou
EGEfstathia Giannopoulou
Efstathia Giannopoulou
STSpyridon Champeris Tsaniras
Spyridon Champeris Tsaniras
CSChaido Sirinian
Chaido Sirinian
VBVasiliki Bravou
Vasiliki Bravou
Background/Aim: Epithelial-mesenchymal transition (EMT) and cancer stem cells (CSC) are critically implicated in cancer metastasis and chemoresistance. Herein, we investigated integrin-linked kinase (ILK)'s role in human colon cancer (CRC) progression and chemoresistance in relation to EMT and CSC markers. Patients and Methods: Expression of ILK, EMT and CSC markers were evaluated by immunohistochemistry in 149 CRC samples. We also generated colon cancer cells resistant to 5-FU and oxaliplatin and studied the effect of ILK inhibition on drug response by MTT assay and on EMT and CSC markers' expression. Results: ILK expression in human CRC correlates with EMT and CSC markers and is associated with metastasis and chemoresistance. ILK inhibition increases sensitivity of resistant cells to 5-FU and oxaliplatin and reduces the levels of EMT and CSC markers in 5-FU resistant cells. Conclusion: ILK overexpression in human CRC associates with EMT and CSC traits, contributing to tumor progression and chemoresistance.

19 January 2018 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
HAHelen Aggelou
Helen Aggelou
PCPanagiota Chadla
Panagiota Chadla
SNSofia Nikou
Sofia Nikou
SKSofia Karteri
Sofia Karteri
IMIoannis Maroulis
Ioannis Maroulis
VBVasiliki Bravou
Vasiliki Bravou

28 April 2010 in Histopathology
Verified
Journal Article
Closed access
PDF file
SPSofia Papanikolaou
Sofia Papanikolaou
VBVasiliki Bravou
Vasiliki Bravou
KGKonstantinos Gyftopoulos
Konstantinos Gyftopoulos
DNDimitrios Nakas
Dimitrios Nakas
MRMaria Repanti
Maria Repanti
HPHelen Papadaki
Helen Papadaki

12 December 2003 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
VBVasiliki Bravou
Vasiliki Bravou
GKG Klironomos
G Klironomos
EPE Papadaki
E Papadaki
DSD Stefanou
D Stefanou
JVJ Varakis
J Varakis
Integrin-linked kinase (ILK) expression in human colon cancer

1 June 2021 in Analytica Chimica Acta
Verified
Journal Article
Closed access
Panagiota M KalligosfyriPanagiota M Kalligosfyri
Panagiota M Kalligosfyri
SNSofia Nikou
Sofia Nikou
VBVasiliki Bravou
Vasiliki Bravou
Despina KalogianniDespina Kalogianni
Despina Kalogianni

12 June 2015 in Cancer Investigation
Verified
Journal Article
Closed access
PDF file
VBVasiliki Bravou
Vasiliki Bravou
AAAnna Antonacopoulou
Anna Antonacopoulou
SPSofia Papanikolaou
Sofia Papanikolaou
SNSofia Nikou
Sofia Nikou
ILIoannis Lilis
Ioannis Lilis
HKHaralabos P. Kalofonos
Haralabos P. Kalofonos
This study aims to address the role of focal adhesion proteins α- and β-parvin in human colorectal carcinoma (CRC). Expression of α- and β-parvin was examined by immunohisto- chemistry and real-time RT-PCR in a series of human CRC. Parvins were overexpressed in CRC and their expression correlated significantly with tumor invasion, lymph node metastasis, and disease stage. A significant positive correlation of parvins protein expression with overexpression of integrin-linked kinase, p-AKT, and nuclear β-catenin, as well as with downregulation of E-cadherin was also observed. In conclusion, overexpression of α- and β-parvin seems to be implicated in human colorectal cancer progression.